Skip to main content

Table 4 PK parameters for piperaquine in the presence and absence of KAF156

From: A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine

PK parametera (unit)

800 mg KAF156 + 1280 mg PPQ

N = 23 (mean, SD, CV%)

1280 mg PPQ

N = 24 (mean, SD, CV%)

Cmax (ng/mL)

409 ± 299 (73.2%) [n = 23]

233 ± 169 (72.3%) [n = 24]

AUClast (h µg/mL)

10.8 ± 6.14 (56.8%) [n = 22]

10.3 ± 4.16 (40.2%) [n = 23]

AUCinf (h µg/mL)

11.9 ± 5.25 (44.1%) [n = 19]

12.0 ± 5.31 (44.2%) [n = 17]

AUC0-24 h (h µg/mL)

2.94 ± 1.81 (61.5%) [n = 22]

2.09 ± 0.993 (47.4%) [n = 24]

AUC0-72 h (h µg/mL)

4.73 ± 2.89 (61.0%) [n = 22]

3.49 ± 1.56 (44.8%) [n = 24]

AUC0-168 h (h µg/mL)

6.35 ± 3.67 (57.9%) [n = 21]

4.82 ± 1.95 (40.4%) [n = 23]

Tmax (h)

3.00 (2.00–4.05) [n = 23]

4.00 (3.00–8.00) [n = 24]

T1/2 (h)

469 ± 170 (36.2%) [n = 19]

509 ± 142 (27.9%) [n = 17]

CL/F (mL/h)

127,000 ± 53,100 (41.7%) [n = 19]

126,000 ± 52,700 (41.9%) [n = 17]

Vz/F (L)

82,200 ± 34,500 (42.0%) [n = 19]

89,100 ± 32,800 (36.8%) [n = 17]

  1. Abbreviations as per Table 3
  2. aAll PK parameter values are presented as mean ± SD (CV%) [n] except Tmax which is presented as median (range) [n]. n is number of subjects providing reliable estimate of the parameter